Physician profile
Catherine Beninati
NPI 1366534737
$2,716.45
in general payments reported to CMS, 2019-2025
17 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.00 · 2020: $171 · 2021: $331 · 2022: $547 · 2023: $537 · 2024: $703 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,642.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $496.72 | 2020-2025 | Vraylar, Mavyret |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $427.67 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $401.23 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $327.96 | 2020-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Gilead Sciences, INC. | $244.38 | 2023-2025 | Epclusa |
| Lundbeck LLC | $169.96 | 2024-2025 | Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $160.36 | 2021-2024 | Invega Sustenna |
| Indivior INC. | $112.35 | 2020-2025 | Sublocade |
| Axsome Therapeutics, INC. | $77.37 | 2023-2025 | Auvelity |
| Glaxosmithkline, LLC. | $72.58 | 2020-2025 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $44.33 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
| Alkermes, INC. | $43.20 | 2019-2021 | |
| Noven Therapeutics, LLC | $36.90 | 2021 | |
| Pfizer INC. | $34.44 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $30.63 | 2024 | Cobenfy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $21.05 | 2024 | Immunocap |
| Orexo US, INC. | $15.32 | 2025 | Zubsolv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Beninati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.